# GHK-Cu Dosage in the Research Literature: Topical, Animal, and Investigational Ranges

> GHK-Cu dosage in published research: topical creams at 0.05–5%, the Lamin 0.4% wound gel, animal injection ranges 1–10 mg/kg, and what the literature does and does not say about human pharmacokinetics.

_Eyebrow: § 03 · DOSAGE LITERATURE_

## GHK-Cu Dosage in the Research Literature

A research-context digest of every published dose, route, and trial duration in the GHK-Cu corpus — topical creams, the diabetic-ulcer wound gel, animal-injection ranges, and the unresolved human-pharmacokinetic gap.

## GHK-Cu dosing in published research

GHK-Cu dosage ranges in published research cluster by route. Topical creams and serums in human trials run 0.05–5% (w/w), applied once or twice daily for 4–12 weeks [5][6][11]. The Lamin wound-care gel evaluated in the Mulder 1994 multicenter placebo-controlled diabetic-foot-ulcer trial used 0.4% GHK-Cu in a collagen-based gel with daily dressing changes [7]. In-vitro cell-culture studies typically apply 1 nM to 10 µM GHK or GHK-Cu [4][12]. Animal-injection studies cited in review-level summaries use 1–10 mg/kg subcutaneous or intraperitoneal [3]. Investigational subcutaneous research protocols in published reviews cite 1–2 mg reconstituted GHK-Cu per dose — but no FDA-approved injectable GHK-Cu formulation exists [3].

## GHK-Cu half-life and pharmacokinetics

Endogenous plasma GHK concentration declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL at age 60 — a ~2.5-fold drop across adulthood [2]. Exogenous-injection pharmacokinetics in humans are not well characterized. No published peer-reviewed Phase 1 PK study on injectable GHK-Cu exists at the time of writing. In vitro, GHK-Cu is rapidly bound by serum albumin (the major plasma copper carrier), which constrains its free systemic half-life. Half-life claims circulating in non-peer-reviewed sources are not traceable to a primary PK paper.

## Subcutaneous GHK-Cu in research settings

Investigational subcutaneous protocols described in published reviews typically use 1–2 mg reconstituted GHK-Cu per dose [3]. No FDA-approved injectable GHK-Cu product exists, and no large randomized controlled trial of injectable GHK-Cu for any indication has been published. The Park (2022) mouse COPD work used intraperitoneal GHK-Cu in a cigarette-smoke-exposure model and reported reduced MDA and ROS, increased SOD and GSH, and preserved alveolar architecture [13] — that is the closest in-vivo systemic-administration data point in the modern corpus, and it is rodent.

## Time-course observed in topical GHK-Cu studies

Pickart's facial-cream trial — the Leyden et al. (2002) study in 71 women with mild-to-advanced photoaging — used twice-daily topical application for 12 weeks and reported reduced fine-line depth, wrinkle depth, and skin roughness, and improved skin laxity, clarity, and density at the 12-week endpoint [5]. The Mulder (1994) Lamin diabetic-ulcer trial measured wound closure over the standard ulcer-care follow-up window with daily dressing changes [7]. The Miller (2006) CO2-laser split-face study followed patients post-procedure on a topical GHK-Cu regimen [7].

## Routes studied across the corpus

The published routes of administration are: topical (cream, serum, gel) — by far the most-published route; intraperitoneal in rodent studies; subcutaneous in rodent studies and investigational human protocols only; ex-vivo tissue exposure (the Pickart 1973 liver-explant work [1]); and preclinical intranasal in rodent neuroprotection work. The Czyrski (2024) Pharmaceutics ex-vivo Franz-cell work measured 0.05–0.1% GHK-Cu, free versus liposomal, across porcine and human skin and reported measurably better stratum-corneum permeation and dermal deposition with the liposomal vehicle [14] — the formulation-engineering frontier of the dose-delivery question.

## Stability and formulation

Solid GHK-Cu is stable when stored desiccated at -20 °C. In aqueous solution the peptide is sensitive to oxidation and to displacement of Cu(II) by competing chelators — EDTA, strong vitamin-C reductants, and low pH all destabilize the complex. Topical formulations commonly stabilize the molecule with controlled pH (5.0–6.5) and avoid co-formulation with strong-acid actives. This stability profile is the chemical basis for the topical-skincare guidance to separate GHK-Cu from high-concentration L-ascorbic-acid vitamin C and from strong retinoid vehicles in a daily routine.

## Human-trial dose summary

Substantive human evidence is dermatological and topical: a 12-week 71-woman facial-cream trial [5], thigh-skin collagen biopsy work [6], a CO2-laser-resurfacing split-face trial [7], and a multicenter placebo-controlled diabetic-foot-ulcer wound-gel trial at 0.4% [7]. There is no FDA-approved injectable GHK-Cu product, no published Phase 1 human pharmacokinetic study of subcutaneous GHK-Cu, and no large randomized controlled trial of injectable GHK-Cu for any indication. The IWGDF 2024 guidance for diabetic-ulcer care does not recommend growth-factor-style adjuncts (which historically include GHK-Cu / Lamin gel) over standard care.

## What this page is not

This page is a research-context summary of doses, routes, and trial parameters that have appeared in the peer-reviewed literature. It is not a dosing protocol, not a recommendation, and not clinical guidance. Where a published trial reports a specific dose, that dose is attributed to the trial — not generalized.

## References cited on this page

[1] Pickart L, Thaler MM. A tripeptide in human serum which prolongs the survival of normal liver cells and stimulates the growth of hepatoma cells. Nature New Biology. 1973;243(124):85-87. — https://pubmed.ncbi.nlm.nih.gov/4351778/
[2] Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. — https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[3] Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. — https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
[4] Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. — https://pmc.ncbi.nlm.nih.gov/articles/PMC5332963/
[5] Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin Care Benefits of Copper Peptide Containing Facial Cream. American Academy of Dermatology Annual Meeting Proceedings. 2002. — https://pmc.ncbi.nlm.nih.gov/articles/PMC4508379/
[6] Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. — https://www.mdpi.com/2079-9284/5/2/29
[7] Mulder GD, Patt LM, Sanders L, Rosenstock J, Altman MI, Hanley ME, Duncan GW. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration. 1994;2(4):259-269. — https://onlinelibrary.wiley.com/doi/10.1046/j.1524-475X.1994.20410.x
[11] Pai V, Bhandari P, Shukla P. Topically applied GHK as an anti-wrinkle peptide. BioImpacts. 2017;7(4). — https://bi.tbzmed.ac.ir/Inpress/bi-30071.pdf
[12] Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, et al. A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. 2012;4(8):67. — https://pmc.ncbi.nlm.nih.gov/articles/PMC4064320/
[13] Park JR, Lee H, Kim SI, Yang SR. Glycyl-L-histidyl-L-lysine-Cu2+ attenuates cigarette smoke-induced pulmonary emphysema and inflammation by reducing oxidative stress pathway. Frontiers in Molecular Biosciences. 2022;9:929185. — https://pmc.ncbi.nlm.nih.gov/articles/PMC9354777/
[14] Czyrski A, Resztak M, Hermann TW, Kus K, Glowka FK. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Pharmaceutics. 2024;16(12):1526. — https://pmc.ncbi.nlm.nih.gov/articles/PMC11721469/

---

A horizontal-timeline reading of the GHK-Cu literature from Pickart 1973 to the 2024 fibrosis and liposomal-permeation work — eleven milestones scanned, copper-binding events marked separately from downstream effects, and signed by no clinic and no vendor.